Reasons to use 5% lidocaine patch Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Jun 30, 2025
DOI: https://doi.org/10.24292/01.MF.0225.10
Keywords:
5% lidocaine patch, peripheral localized neuropathic pain, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, carpal tunnel syndrome

Main Article Content

Anna Przeklasa-Muszyńska
Zakład Badania i Leczenia Bólu, Katedra Anestezjologii i Intensywnej Terapii, Collegium Medicum Uniwersytetu Jagiellońskiego

Abstract

This article discusses the problem of peripheral localized neuropathic pain. One of the therapeutic choices in this condition is 5% lidocaine patches. Local treatment with lidocaine is characterized by direct action at the site of pain, which minimizes systemic side effects and drug interactions, as well as low absorption into the systemic circulation (1–5% of the dose), which translates into a better safety profile. 5% lidocaine patches are registered for the treatment of postherpetic neuralgia, but clinical and observational studies also indicate their effectiveness in diabetic polyneuropathy, posttraumatic neuropathy or carpal tunnel syndrome.


Expert recommendations, including International Association for the Study of Pain Neuropathic Pain Special Interest Group and European Federation of Neurological Societies, indicate 5% lidocaine patches as a second-line drug in peripheral neuropathic pain, and even first-line in the elderly and with multimorbidity, due to the limited possibility of using systemic drugs in these patient groups.

Article Details

How to Cite
Przeklasa-Muszyńska, A. (2025). Reasons to use 5% lidocaine patch. Medycyna Faktow (J EBM), 18(2(67), 234-238. https://doi.org/10.24292/01.MF.0225.10
Issue
Vol 18 No 2(67) (2025)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015; 14: 162-73.
2. Moisset X, Bouhassira D, Couturier JA et al. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev. Neurol. 2020; 176: 325-52.
3. IASP. IASP taxonomy. 2019.
4. Raja SN, Ringkamp M, Guan Y et al. Bonica Award Lecture: Peripheral neuronal hyperexcitability: The “low-hanging” target for safe therapeutic strategies in neuropathic pain. Pain. 2020; 161: S14-26.
5. Kocot-Kępska M, Zajączkowska R, Mika J et al. Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain – Narrative Review. Pharmaceutics. 2021; 13: 450.
6. Kocot-Kępska M, Zajączkowska R, Mika J et al. Peripheral Mechanisms of Neuropathic Pain – The Role of Neuronal and Non-Neuronal Interactions and Their Implications for Topical Treatment of Neuropathic Pain. Pharmaceuticals. 2021; 14: 77.
7. Moisset X. Neuropathic pain: Evidence based recommendations. La Presse Médicale. 2024; 53(2): 104232.
8. Finnerup N, Haroutounian S, Baron R et al. Neuropathic pain clinical trials: Factors associated with decreases in estimated drug efficacy. Pain. 2018; 159: 2339-46.
9. Pickering G, Martin E, Tiberghien F et al. Localized neuropathic pain: an expert consensus on local treatments. Drug Des Devel Ther. 2017; 11: 2709-18.
10. Bursi R, Piana C, Grevel J et al. Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients. Eur J Drug Metab Pharmacokinet. 2017; 42(5): 801-14.
11. Chahine M, O’Leary ME. Regulation/Modulation of Sensory Neuron Sodium Channels. Handb Exp Pharmacol. 2014; 221: 111-35.
12. Charakterystyka produktu leczniczego. Versatis.
13. Wasner G, Kleinert A, Binder A et al. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol. 2005; 252: 677-86.
14. Khaliq W, Alam S, Puri NK. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev. 2013; 2013(10): CD004846.
15. Davies P, Galer B. Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic Neuralgia. Drugs. 2004; 64: 937-47.
16. Baron R, Mayoral V, Leijon G et al. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 2009; 29(4): 231-41.
17. Casale R, Mattia C. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: Focus on 5% lidocaine-medicated plaster. Ther Clin Risk Manag. 2014; 10: 259-68.
18. Mick G, Baron R, Finnerup NB et al. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag. 2012; 2: 71-7.
19. Casale R, Symeonidou Z, Bartolo M. Topical Treatments for Localized Neuropathic Pain. Curr Pain Headache Rep. 2017; 21: 15.
20. Grillo R, Leal M, Campanha A et al. Effectiveness of lidocaine patches in the treatment of post-herpetic neuralgia on the face: a systematic review and meta-analysis. Res Soc Dev. 2021; 10(13): e482101321513.
21. Bouhassira D, Attal N, Fermanian J et al. Development and validation of the neuropathic pain symptom inventory. Pain. 2004; 108: 248-57.
22. Derry S, Wiffen PJ, Moore RA et al. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014; 7: CD010958.
23. Mick G, Correa-Illanes G. Topical pain management with the 5% lidocaine medicated plaster – a review. Curr Med Res Opin. 2012; 28(6): 937-51.